CLOZAPINE AND AGRANULOCYTOSIS: IMPACT OF THE RISK EVALUATION AND MITIGATION STRATEGY PROGRAM

被引：0
|
作者：
Borrelli, E. P. [1 ]
Lee, E. Y. [1 ]
Descoteaux, A. M. [1 ]
Caffrey, A. R. [1 ]
机构：
[1] Univ Rhode Isl, Coll Pharm, Kingston, RI 02881 USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.1228
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMH1
引用
收藏
页码：S180 / S180
页数：1
相关论文
共 50 条
  • [31] Impact of hereditary variants in the neutrophilic oxidation system to clozapine-induced agranulocytosis
    Mossiaguine, I
    Dettling, M
    Mueller-Oerlinghausen, B
    Roots, I
    Cascorbi, I
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 365 : R117 - R117
  • [32] Pathomechanisms of clozapine-induced agranulocytosis-impact of genetic determinants.
    Dettling, M
    MullerOerlinghausen, B
    Roots, I
    Rolfs, A
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1997, 355 (04) : 431 - 431
  • [33] Incidence and risk for neutropenia/agranulocytosis among clozapine users: A retrospective cohort study
    Ratanajamit, Chaveewan
    Musakopas, Chutima
    Vasiknanonte, Sorayut
    Reanmongkol, Wantana
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2010, 14 (02) : 109 - 115
  • [34] Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring
    Schulte, PFJ
    ANNALS OF PHARMACOTHERAPY, 2006, 40 (04) : 683 - 688
  • [35] History of the Asian Lymantria species Program: A Unique Pathway Risk Mitigation Strategy
    Mastro, Victor C.
    Munson, A. Steve
    Wang, Baode
    Freyman, Tamara
    Humble, Leland M.
    Coyle, David
    JOURNAL OF INTEGRATED PEST MANAGEMENT, 2021, 12 (01)
  • [36] The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program - Current Status and Future Direction
    Wu, Jasmanda
    Juhaeri, Juhaeri
    CLINICAL THERAPEUTICS, 2016, 38 (12) : 2526 - 2532
  • [37] Medication Management of Early Pregnancy Loss: The Impact of the US Food and Drug Administration Risk Evaluation and Mitigation Strategy
    Neill, Sara
    Goldberg, Alisa
    Janiak, Elizabeth
    OBSTETRICS AND GYNECOLOGY, 2022, 139 : 83S - 83S
  • [38] Potassium chloride for injection concentrate: Time for a risk evaluation and mitigation strategy
    Knox, Caitlin A.
    Liu, Wei
    Brushwood, David B.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (03) : 238 - 242
  • [39] Contraception Special Issue on the mifepristone Risk Evaluation and Mitigation Strategy (REMS)
    Cleland, Kelly
    Foster, Angel M.
    Gomez, Anu Manchikanti
    Raymond, Elizabeth G.
    Westhoff, Carolyn L.
    CONTRACEPTION, 2021, 104 (01) : 1 - 3
  • [40] Inpatient pharmacy experience with an audit for a risk evaluation and mitigation strategy for riociguat
    Smith, Zachary R.
    Makowski, Charles T.
    MacDonald, Nancy C.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2017, 74 (21) : 1762 - 1763
12345